Please update your Flash Player to view content.

Bio Pro Classes:

 
Monday, 06 Apr 2015 - Monday, 27 Jul 2015
Category: Bio Pro Classes

 
Monday, 06 Apr 2015 - Monday, 08 Jun 2015
Category: Bio Pro Classes

 
Tuesday, 07 Apr 2015 - Wednesday, 29 Apr 2015
Category: Bio Pro Classes

 
Wednesday, 08 Apr 2015 - Thursday, 09 Apr 2015
Category: Bio Pro Classes

 
Wednesday, 15 Apr 2015 - Thursday, 16 Apr 2015
Category: Bio Pro Classes

 
Monday, 20 Apr 2015
Category: Bio Pro Classes

 
Tuesday, 21 Apr 2015 - Wednesday, 22 Apr 2015
Category: Bio Pro Classes

 
Thursday, 30 Apr 2015
Category: Bio Pro Classes

 
Thursday, 14 May 2015
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

 SBIR 101: How to create a competitive SBIR grant application.

 

Dr FarellThis is a must attend event for any entrepreneur trying to pursue SBIR and other forms of government grant funding. Dr. David Farrell will share decades of experience successfully soliciting federal grants (SBIR, STTR, etc.) from the federal government. Unlike other seminars and workshops, Dr. Farrell takes a hands on approach. From teaching you the history of the programs, to actually logging onto the relevant sites and completing registration forms, participants complete the practical steps necessary to jumpstart their submissions.

 

Dr. Farrell's workshop will cover the broadest spectrum of federal programs, including SBIR/STTR programs for the National Science Foundation (NSF), United States Department of Agriculture (USDA), and the Environmental Protection Agency (EPA), with an emphasis on the National Institutes of Health (NIH). In addition, the huge Department of Defense budget will also be explored, including a few little-known pots of money--including: the Congressionally Directed Medical Research Programs (CDMRP), Air Force, Defense Advanced Research Projects Agency (DARPA), Navy, Defense Threat Reduction Agency (DTRA), and Army SBIR/STTR programs and other non-SBIR contract programs.

 

This interactive session will include attendees downloading onto their own laptops each of the subsections of the application forms while Dr. Farrell explains proven strategies for creating competitive applications. This class is focused on overcoming the barriers standing between you and a funded grant.

 

Cost: Members $225, Non-members $300

Date and Time: March 5, 2014 from 1 p.m. to 5:00 p.m.

Location: OTRADI Business Incubator, 4640 SW Macadam, Suite #240

 

News Flash

  • Genentech announces plans to expand Hillsboro facility

    Investment to bring up to 100 new jobs to Oregon

    South San Francisco, Calif. – March 26, 2015 – Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon. “This investment in our sterile production operations will result in the addition of up to 100 new skilled manufacturing jobs in the greater Portland area over the next five years, potentially bringing the total number of Genentech jobs in Oregon to over 500,” said Larry Sanders, General Manager and Vice President, Hillsboro Technical Operations.

    “This announcement is another indicator that this is an exciting time in Oregon’s history,” said Governor Kate Brown. “Genentech’s investment in its Hillsboro campus and Oregon’s robust workforce underscore that Oregon is a great place for all businesses to build their future and for the biotech sector to grow.”

    Genentech opened operations in Hillsboro in April 2010. The site is home to a state-of-the-art fill/finish facility and warehousing and distribution center. Genentech's product pipeline is among the strongest in the biotechnology and pharmaceutical industries, and demand for its marketed products continues to grow. The expansion of operations at the Hillsboro site is part of the company’s strategy to increase manufacturing capacity to meet that demand.-

    “Genentech’s plan to expand its Hillsboro facility represents an important milestone in the industry’s growth trajectory in Oregon. Combined with other recent achievements like the historic Knight Cancer Challenge, Oregon is positioned to significantly expand our life sciences manufacturing footprint,” said Dennis McNannay, Executive Director of the Oregon Bioscience Association.

    About Biologics Manufacturing
    Genentech was the first biotechnology company to scale up protein manufacturing successfully from the small quantities used for research to the much larger quantities needed for clinical trials and marketing. Today Genentech and Roche are a world leader in biologics manufacturing, with more FDA-approved manufacturing capacity for the production of biotech medicines than any other company. Over the last two decades, Genentech has built world-class production facilities, developed expertise in commercially viable manufacturing processes, and also attracted and retained key personnel with experience in all aspects of large-scale biologics manufacturing. Genentech's manufacturing expertise, capacity and portfolio of capacity enhancement projects position the company well to meet the internally forecasted demands for our products. Our dedication to world-class biologics manufacturing and our careful planning for the future will assist us in continuing to deliver innovative therapies to patients with serious and life-threatening diseases.

    About Genentech
    Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

    ###

    Media Contact:  Robin Snyder (650) 467-6800

Bioscience News

  • Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ MarketSite in New York. Joining him on the stage were a number of BIO members and affiliates, including NewYorkBIO Executive Director Nathan Tinker, Pennsylvania Bio President Christopher Molineaux, DelawareBio Chairman Christopher Yochim, and BioNJ President Debbie Hart. Several BIO member companies were also represented, including Acorda Therapeutics President and CEO Ron Cohen, who also serves as Vice Chair of BIO’s Read More >

  • In recent news, the International Agency for Research on Cancer (IARC) announced that it has labeled the widely used herbicide glyphosate as “probably carcinogenic” to humans in its upcoming review of the product.  Unfortunately, since IARC is an agency of the World Health Organization, the report has been seen as having some credibility. However the report is not as accurate as it appears.  GMO Answers expert Dr. Michael Greenberg explains his post flaws within IARC’s findings: Read More >

  • Nominations are now open for the Buzz of BIO at the 2015 BIO International Convention! The Buzz of BIO contest recognizes highly innovative companies in the biotech sector and helps position these companies to develop strategic partnerships within the industry. Nominate Your Company Twenty biotechs will be nominated in each of the two categories – Pipelines of Promise and Technologies of Tomorrow. Qualifying companies for “Pipelines of Promise” are companies that have at least started Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2014. All Rights Reserved.